Arthritis in Medical Technology

Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial

SOUTH SAN FRANCISCO, Calif., July 9 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that R788 (fostamatinib disodium) produced significant clinical improvement in rheumatoid arthritis (RA) patients in the recently completed TASKi2 Phase 2b clinical trial of ...

SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Positive Opinion Recommends Approval of New Anti-TNF Therapy in Three Rheumatic Diseases with Novel SmartJect(TM) Autoinjector HORSHAM, Pa. and KENILWORTH, N.J., June 26 /PRNewswire-FirstCall/ -- Centocor Ortho Biotech Inc. and Schering-Plough Corporation (NYSE: SGP ) announced today that t...

Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome

Findings Published in Nature Medicine Suggest Broad Implications for the Treatment of Inflammatory and Autoimmune Disorders SOUTH SAN FRANCISCO, Calif., June 15 /PRNewswire/ -- Proteolix, Inc. announced that in an article published today in Nature Medicine, Proteolix's selective immunoprote...

New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients

Anti-TNF Experienced Patients Demonstrated Improvement With Every-Four-Week Subcutaneous SIMPONI Despite Previous Medication or Reason for Discontinuation COPENHAGEN, June 9 /PRNewswire/ -- A new analysis demonstrated that a greater proportion of patients with moderately to severely active rh...

Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis

Long-Term Data in Patients Receiving Every-Four-Week Subcutaneous SIMPONI Presented at 2009 EULAR Annual Congress COPENHAGEN, June 9 /PRNewswire/ -- Findings from open-labeled, uncontrolled extensions of two randomized, placebo-controlled Phase 3 studies showed that subcutaneous (SC) inject...

Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients

- Additional data reinforce long-term efficacy of ACTEMRA across a broad range of rheumatoid arthritis patient populations - NUTLEY, N.J., June 9 /PRNewswire/ -- One-year data from the two-year Phase III LITHE (Toci LI zumab Safety and THE Prevention of Structural Joint Damage) study de...

Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients

- Fifth International Phase III ACTEMRA Study Meets its Primary Endpoints - NUTLEY, N.J., May 25 /PRNewswire/ -- Roche today announced that two-year data from the LITHE (Toci LI zumab Safety and THE Prevention of Structural Joint Damage) study demonstrated that ACTEMRA(R) (tocilizumab...

Fast-Acting, Long-Lasting Topical Relief From Arthritis Pain

Medicated Arthri-Zen Relief Cream(R) Clinically Shown to Work for up to 8 Hours MIAMI, March 11 /PRNewswire/ -- Every day, 70 million Americans suffer from the aches and pains that come with arthritis and other chronic joint problems(1). One of the most effective ways to get fast relief from ...

New Treatment Against Osteoarthritis: Orthokine Therapy Highly Effective Against Knee Arthritis After Two Years

DÿSSELDORF, Germany, February 23 /PRNewswire/ -- An international team of researchers has evaluated the effectiveness of Orthokine therapy for osteoarthritis of the knee, and the results have been published in the February edition of the specialist journal "Osteoarthritis and Cartilage". The ...

Rigel's R788 Phase 2a Results Published in Arthritis and Rheumatism

First of Phase 2b studies completes patient screening for enrollment SOUTH SAN FRANCISCO, Calif., Nov. 11 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that the previously reported results of the Phase 2 clinical trial of R788 (fostamatinib disodium),...

CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years

CIMZIA(R) Data Shows Long-term Improvements in Productivity, Quality of Life and Lessened Fatigue According to Studies Presented at American College of Rheumatology (ACR) Annual Scientific Meeting SAN FRANCISCO, Oct. 27 /PRNewswire/ -- 5:00 AM PST -- UCB announced today results from se...

New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients

- One-year study results showed improved physical function in patients treated with ACTEMRA - NUTLEY, N.J., Oct. 25 /PRNewswire/ -- One-year data from a two-year Phase III study demonstrated that ACTEMRA(R) (tocilizumab) significantly inhibited the progression of structural joint damage in p...

ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments

- Results of two Phase III studies affirmed the clinical benefits of ACTEMRA - NUTLEY, N.J., Oct. 25 /PRNewswire/ -- Data from two Phase III studies showed that patients who suffer from the debilitating and painful effects of rheumatoid arthritis (RA) achieved significant improvements in sig...

ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies

- Phase III monotherapy study shows ACTEMRA is first and only biologic to demonstrate statistical superiority over methotrexate after 24 weeks of treatment - PARIS, June 13 /PRNewswire/ -- Patients who suffer the chronic and debilitating effects of rheumatoid arth...

Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study

COPENHAGEN, Denmark, June 10 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today a Phase I/II study to evaluate a subcutaneous route of administration of ofatumumab (HuMax-CD20(R)) in rheumatoid arthritis (RA) patients, stable on methotrexate will be initiated soon. The study, whic...

Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma

SUNNYVALE, Calif., June 9 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC ) today announced results from a preclinical study evaluating PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, in collagen induced arthritis, an established animal mod...

New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients

- Fifth International Phase III Study Shows Positive Results with X-ray Data - NUTLEY, N.J., May 9 /PRNewswire/ -- Roche today announced one-year results from a new two-year Phase III study showing that ACTEMRA(TM) (tocilizumab) can significantly inhibit progres...

U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older

- ORENCIA is a First-in-Class Biologic Treatment Option Now Available for Use in Pediatric Patients with JIA(1,2) - PRINCETON, N.J., April 8, 2008 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY ) today announced that the U.S. Food and Drug Administration (FDA) ...

International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet

- By targeting interleukin-6 receptors, ACTEMRA provides significant benefits for patients when compared with existing therapies - NUTLEY, N.J., March 20 /PRNewswire/ -- Patients with rheumatoid arthritis treated with Roche's ACTEMRA(TM) (tocilizumab) experienced significant and rapid re...

Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study

Achieves Statistically Significant ACR20, ACR50 & ACR70 Results SOUTH SAN FRANCICSO, Calif., Dec. 13 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that its oral syk kinase inhibitor, R788 (tamatinib fosdium), has demonstrated statistically significa...

Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)

ATLANTA, Dec. 11 /PRNewswire-USNewswire/ -- The Arthritis Foundation, the leading health organization addressing the needs of 46 million Americans living with arthritis, today announced that Amgen and Wyeth Pharmaceuticals, co-marketers of Enbrel (R) (etanercept), will be the national presenti...

Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)

- Data presented at American College of Rheumatology Annual Congress - BOSTON, Nov. 12 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY ) today announced the results of three post-hoc analyses from two Phase III pivotal trials that showed ORENCIA(R) (abatacept) improved dail...

Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate

- Data Presented at American College of Rheumatology Annual Meeting - BOSTON, Nov. 9 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY ) today announced that cumulative five-year data from an open-label long-term extension of a Phase IIb trial demonstrate the long-term effica...

Two Pivotal Phase III Studies for Roche's ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms

- New data from TOWARD study highlight significant improvements in RA symptoms achieved with the unique inhibiting action of ACTEMRA that specifically targets interleukin-6 receptors - NUTLEY, N.J., Nov. 7 /PRNewswire-FirstCall/ -- Data from two pivotal multinational Phase III cl...

CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year

Two Large Phase III Trials Confirm Robust Efficacy of CIMZIA BOSTON, Nov. 7 /PRNewswire/ -- UCB announced today the results of new Phase III data from the RAPID 1 and 2 studies presented at the American College of Rheumatology Annual Scientific Meeting (ACR), which show CIMZIA(R) (certol...

New Risk Gene for Rheumatoid Arthritis and Lupus Opens Door to More Effective Treatments

MANHASSET, N.Y., Sept. 6 /PRNewswire-USNewswire/ -- Scientists at The Feinstein Institute for Medical Research have identified a critical gene that increases a person's risk for rheumatoid arthritis and systemic lupus erythematosus, and may be involved with other autoimmune diseases. The gene...

ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review

NEW YORK, Aug. 7 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY ) today announced that the U.S. Food and Drug Administration (FDA) has accepted, for filing and review, the supplemental biologics license application (sBLA) for ORENCIA(R) (abatacept) for the treatment of pedi...

Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis

SOUTH SAN FRANCISCO, Calif., July 8 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that the Company plans to host a conference call on Thursday, July 9, 2009 at 8:00 am EDT (5:00 am PDT). Members of Rigel's senior management team and the principal investig...

Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis

DALLAS, July 7 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today new preclinical data demonstrating that thiarabine shows remarkable efficacy in the prevention and treatment of rheumatoid arthritis (RA). In a well-established animal model...

Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis

Top-line data indicate statistically significant improvement in ACR20 responses over placebo PRINCETON, N.J., May 14 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) today announced that the MDX-1100 Phase 2 proof-of-concept trial in patients with active rheumatoid arthritis (RA) rec...

Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis

VIENNA, Va., Sept. 5 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (Amex: CVM ) announced today that it presented new rheumatoid arthritis data at the Marcus Evans conference on Immunogenicity in Amsterdam. The data, presented by Dr. Daniel Zimmerman, Senior Vice President of Research, Cellul...

New Research Shows Promise for Finding A Cure for Rheumatoid Arthritis

The American College of Rheumatology Research and Education Foundation's Within Our Reach Campaign Yields Significant Advances in Detecting, Treating and Understanding RA ATLANTA, Sept. 3 /PRNewswire/ -- For the first time during its unprecedented initiative to find a cure...

Pediatric Researchers Find Possible 'Master Switch' Gene in Juvenile Arthritis

PHILADELPHIA, July 1 /PRNewswire-USNewswire/ -- Researchers have found that a gene region known to play a role in some varieties of adult rheumatoid arthritis is also present in all types of childhood arthritis. The researchers say the responsible gene may be a "master switch" that helps turn ...

Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis

Patients Receiving Every Four-Week Subcutaneous Golimumab Also Experienced Improvements in Physical Function and Disease Activity PARIS, June 11 /PRNewswire/ -- Findings from two new Phase 3 studies showed that patients receiving every four-week subcutaneous injections of golimumab (CNT...

Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis

Presentation of Phase 1 Clinical Data of MDX-1100 at Digestive Disease Week 2008 PRINCETON, N.J., May 12 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) announced today that it has initiated the Phase 2 clinical development program of MDX-1100, a fully h...

Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis

Study to Evaluate Preferred Induction Dosing Regimen SEATTLE, May 7 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN ) today announced that its partner, Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE ), has commenced patient dosing in the next Phase 2b cl...

Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis

First Patient Dosed in Phase 1 Trial of SBI-087, Trubion's Next-Generation Candidate SEATTLE, April 21 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN ) today announced that its collaboration partner Wyeth Pharmaceuticals, a division of Wyeth ...

Current and Emerging Drugs Have No Advantage Over Enbrel in Inhibiting/Slowing the Progression of Rheumatoid Arthritis

Although Some Emerging Therapies Hold Promise, Enbrel Will Remain the Clinical Gold Standard Through 2016, According to a New Report from Decision Resources WALTHAM, Mass., April 7, 2008 /PRNewswire/ -- Decision Resources, one of the world's leading research and adv...

Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis

CAMBRIDGE, Mass., March 14 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. today announced that enrollment has been completed in a Phase 2 trial of 100 patients that evaluates the safety and efficacy of its lead product, MM-093, in patients suffering from rheumatoid arthritis (RA). MM-093 is a...

MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis

GAITHERSBURG, Md., Nov. 26 /PRNewswire/ -- MedImmune, Inc. today announced that dosing of patients has begun in the first Phase 1 clinical trial of CAM- 3001, a fully human monoclonal antibody (MAb) targeting the alpha subunit of the granulocyte-macrophage colony stimulating factor receptor (G...